ACTR-50. MARIZOMIB (MRZ) WITH BEVACIZUMAB (BEV) IN WHO GRADE IV MALIGNANT GLIOMA (G4 MG): FULL ENROLLMENT RESULTS FROM THE PHASE 1, MULTICENTER, OPEN-LABEL STUDY

Daniela A. Bota,Annick Desjardins,Warren P. Mason,Howard A. Fine,Santosh Kesari,Steven D. Reich,Anshu Vashishtha,Nancy Levin,Mohit Trikha

ACTR-50. MARIZOMIB (MRZ) WITH BEVACIZUMAB (BEV) IN WHO GRADE IV MALIGNANT GLIOMA (G4 MG): FULL ENROLLMENT RESULTS FROM THE PHASE 1, MULTICENTER, OPEN-LABEL STUDY

2016

Daniela A. Bota
Annick Desjardins
Warren P. Mason
Howard A. Fine
Santosh Kesari
Steven D. Reich
Anshu Vashishtha
Nancy Levin
Mohit Trikha

Author(s): Bota, Daniela; Desjardins, Annick; Mason, Warren; Fine, Howard; Kesari, Santosh; Reich, Steven D; Vashishtha, Anshu; Levin, Nancy; Trikha, Mohit

Keywords:

Bevacizumab
Pathology
Cancer research
Medical physics
Glioma
Medicine
Nuclear medicine
Oncology
open label study
Internal medicine
who grade

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations